Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands-Reference-Cited by-同舟云学术

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands

Published:2022-03-07 Issue:6 Volume:65 Page:4709-4726
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhao Hong-Yi¹^ORCID,Wang Hai-Peng²,Mao Yu-Ze¹,Zhang Hao³^ORCID,Xin Minhang¹^ORCID,Xi Xiao-Xiao¹,Lei Hao¹,Mao Shuai¹^ORCID,Li Dong-Hui²,Zhang San-Qi¹

Affiliation:

1. Department of Medicinal Chemistry, School of Pharmacy, Xi’an Jiaotong University Health Science Center, Xi’an 710061, Shaanxi, P. R. China

2. Department of Medical Oncology, Shaanxi Provincial People’s Hospital, Xi’an 710068, Shaanxi, P. R. China

3. State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Lunan Pharmaceutical Group Co., LTD., Linyi 276000, Shandong, P. R. China

Funder

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01827

Reference45 articles.

1. Targeted therapies in the treatment of advanced/metastatic NSCLC

2. Lung cancer: New biological insights and recent therapeutic advances

3. MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer

4. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

5. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

3. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins;European Journal of Medicinal Chemistry;2024-06

4. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives;International Journal of Molecular Sciences;2024-05-07

5. Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions;European Journal of Medicinal Chemistry;2024-05